Budiodarone
Budiodarone is a Phase 3 enabled potentially best-in-class mixed ion channel blocker with esterase metabolism and thus a significantly shorter half-life than amiodarone with no evidence of accumulation to date in human or animal studies, whilst having superior efficacy due to its enhanced late sodium channel blocking properties.
It has been shown to treat AF by controlling symptoms, eliminating LEAF, reducing AF burden, and maintaining normal sinus rhythm.
Wearable devices enable a passive, cost-effective and intuitive method of monitoring AF with a wide installed base for AF duration and burden monitoring without the need for clinic visits.
We intend to enter late-stage clinical trials using a combination of budiodarone with wearable devices to create a complete package for early detection and treatment to improve long-term outcomes in AF.